Clinical Trial Detail

NCT ID NCT02957968
Title Neoadj Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Virginia Commonwealth University
Indications

Her2-receptor negative breast cancer

Therapies

Cyclophosphamide + Doxorubicin + Paclitaxel

Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel

Age Groups: adult senior

Additional content available in CKB BOOST